KRAS and head and neck squamous cell carcinoma: In recent years, the use of anti-EGFR mAbs has played an increasing role in the treatment of several solid tumour types including non-small-cell lung carcinoma (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC) in which KRAS mutation is not detected.